NASDAQ:ABBV 30 January 2026 - 31 January 2026

AbbVie shares rose 1.17% to $223.01 Friday, outperforming a broader market dip after Donald Trump nominated Kevin Warsh to lead the Federal Reserve. Trading volume in AbbVie topped its 50-day average ahead of next week’s earnings report. The stock remains about 9% below its 52-week high. AbbVie will release results and hold its earnings call early Wednesday.

AbbVie shares rose about 1% Friday, closing near $222.73 ahead of its Feb. 4 earnings report and first 2026 guidance. Investors are watching Botox pricing risks after Medicare listed it for price negotiations, and new aesthetics data from Paris. The stock dropped 2.35% Wednesday, ending a five-day rally. Goldman Sachs kept a neutral rating with a $223 target.